Riskpilot← Back to searchSign inGet full accessMediqip AB
ABActiveOrg 5567627418Danska Gränd 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20080 employees
Revenue 2025
SEK 2,1M
-38% vs 2024
EBITDA margin
21.8%
+144% vs 2024
Equity ratio
83.4%
Financial strength
Net profit 2025
SEK 363K
+138% vs 2024
| Revenue | SEK 2,1M | -38% |
| EBITDA | SEK 459K | +144% |
| Net profit | SEK 363K | +138% |
| Total assets | SEK 2,4M | +9% |
| Equity | SEK 2M | +22% |
| Employees | 0 | — |
Legal name
Mediqip AB
Org number
5567627418
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
23 juli 2008
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets verksamhet ska vara att importera och sälja forskningsprodukter till läkemedelsföretag och universitetssjukhus samt därmed förenlig verksamhet. Vi bedriver även konsultverksamhet inom ekonomi och företagsadministration.
Address
Danska Gränd 2
Email
ase@mediqip.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 3 316 | 4 499 | 4 639 | 4 282 | 4 519 | 4 988 | 3 423 | 2 110 |
| Staff expenses | — | — | — | — | — | — | −878 | −1 018 | −487 | −99 |
| EBITDA | 414 | 244 | 210 | 567 | 811 | 924 | 780 | 910 | 188 | 459 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| EBIT | 414 | 244 | 210 | 567 | 811 | 924 | 780 | 910 | 188 | 459 |
| Net financials | 1 | — | — | — | 24 | — | — | 4 | 12 | 8 |
| Profit before tax | 607 | 184 | 210 | 567 | 834 | 925 | 840 | 914 | 199 | 466 |
| Tax | −135 | −43 | −52 | −130 | −186 | −206 | −180 | −195 | −47 | −104 |
| Net profit | 472 | 141 | 158 | 437 | 648 | 719 | 659 | 720 | 153 | 363 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 060 | 971 | 1 027 | 1 471 | 2 067 | 2 734 | 2 692 | 2 149 | 2 220 | 2 426 |
| Equity | 624 | 265 | 423 | 760 | 1 009 | 1 327 | 1 987 | 1 507 | 1 659 | 2 022 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 436 | 646 | 543 | 651 | 999 | 1 347 | 706 | 643 | 561 | 404 |
| Total debt | 436 | 646 | 543 | 651 | 999 | 1 347 | 706 | 643 | 561 | 404 |
EBITDA margin
21.8%
This company
15.8%
Market median
+38% vs market
20162025
Equity ratio
83.4%
This company
38.2%
Market median
+118% vs market
20162025
Return on equity
17.9%
This company
18.4%
Market median
+3% vs market
20162025
Net profit margin
17.2%
This company
8.1%
Market median
+112% vs market
20162025
Asset turnover
0.87×
This company
1.12×
Market median
+22% vs market
20162025
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mediqip AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Marcus Holmberg | Audit | 0 companies |
| Lars Jimmy Viklund | Deputy Board Member | 0 companies |
| Åse Erlandsson | Board of Directors | 0 companies |
| Therese Helena Erika Larsson | Deputy Board Member | 0 companies |